CLINICAL_TRIALS ClinicalTrials.gov record update

The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy With Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric Patients With Refractory Or Recurrent Brain Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02015728
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:21.260436+00:00
Published At: 2016-12-15T00:00:00+00:00
Record Updated At: 2016-12-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Childhood Brain Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2016-12-15"
protocolSection.identificationModule.nctId: "NCT02015728"
protocolSection.identificationModule.officialTitle: "The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy With Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric Patients With Refractory Or Recurrent Brain Tumors"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["NA"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.